paroxetine has been researched along with clonazepam in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (25.93) | 18.2507 |
| 2000's | 7 (25.93) | 29.6817 |
| 2010's | 10 (37.04) | 24.3611 |
| 2020's | 3 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Adler, LA; Angrist, BM | 1 |
| Lillywhite, AR; Nutt, DJ; Wilson, SJ | 1 |
| Lima, L; Trejo, E; Urbina, M | 1 |
| Carpenter, LL; Epperson, CN; McDougle, CJ; Price, LH | 1 |
| Stein, MB | 1 |
| Hoffman, RS; Rella, JG | 1 |
| Baldwin, DS; Birtwistle, J | 1 |
| Doyle, AL; Otto, MW; Peters, P; Pollack, MH; Simon, NM; Toshkov, F; Worthington, JJ | 1 |
| Seedat, S; Stein, MB | 1 |
| Davidson, JR | 1 |
| Miller, KM; Murray, KL; Pearson, DL | 1 |
| Garner, B; Hetrick, SE; Parslow, R; Purcell, R | 1 |
| Amrein, R; Crippa, JA; da Costa, RT; de Carvalho, MR; de Cerqueira, AC; de O E Silva, AC; de-Melo-Neto, VL; Dias, GP; Freire, RC; Hallak, JE; King, AL; Levitan, MN; Mezzasalma, MA; Mochcovitch, MD; Nardi, AE; Nascimento, I; Sardinha, A; Soares-Filho, GL; Valença, AM; Veras, AB; Versiani, M | 1 |
| Amrein, R; Crippa, JA; da Costa, RT; de Carvalho, MR; de Cerqueira, AC; de O e Silva, AC; de-Melo-Neto, VL; Dias, GP; Freire, RC; Hallak, JE; King, AL; Levitan, MN; Mezzasalma, MA; Nardi, AE; Nascimento, I; Sardinha, A; Soares-Filho, GL; Valença, AM; Veras, AB; Versiani, M | 1 |
| Abaitua, I; Alonso-Ferreira, V; Hens, MJ; Posada de la Paz, M; Villaverde-Hueso, A | 1 |
| Amrein, R; Crippa, JA; da Costa, RT; de Carvalho, MR; de Cerqueira, AC; de-Melo-Neto, VL; Dias, GP; E Silva, AC; Freire, RC; Hallak, JE; King, AL; Levitan, MN; Mezzasalma, MA; Mochcovitch, MD; Nardi, AE; Nascimento, I; Paes, F; Sardinha, A; Soares-Filho, GL; Valença, AM; Veras, AB; Versiani, M | 1 |
| Patterson, B; Van Ameringen, M | 1 |
| Amrein, R; Arias-Carrión, O; Carta, MG; Dias, GP; Freire, RC; Machado, S; Mochcovitch, MD; Nardi, AE; Versiani, M | 1 |
| Das, N; Garg, K; Kumar, CN | 1 |
| Bhatia, MS; Daral, A; Goyal, S; Singh, A | 1 |
| Kenda, M; Sollner Dolenc, M; Zore, T | 1 |
| Barbui, C; Bighelli, I; Caldwell, DM; Cipriani, A; Davies, SJ; Dawson, S; Dias, S; Furukawa, TA; Guaiana, G; Imai, H; Koesters, M; Meader, N; Pompoli, A; Robertson, L; Tajika, A | 1 |
7 review(s) available for paroxetine and clonazepam
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.
Topics: 1-Naphthylamine; Adult; Aged; Antidepressive Agents; Buspirone; Child; Clomipramine; Clonazepam; Costs and Cost Analysis; Dopamine Antagonists; Drug Interactions; Drug Tolerance; Fenfluramine; Fluoxetine; Fluvoxamine; Humans; Lithium; Obsessive-Compulsive Disorder; Paroxetine; Risk Assessment; Selective Serotonin Reuptake Inhibitors; Sertraline; Tryptophan | 1996 |
Medication treatments for panic disorder and social phobia.
Topics: Antidepressive Agents, Tricyclic; Benzamides; Benzodiazepines; Citalopram; Clinical Trials as Topic; Clomipramine; Clonazepam; Dose-Response Relationship, Drug; Female; Humans; Male; Moclobemide; Monoamine Oxidase Inhibitors; Panic Disorder; Paroxetine; Piperidines; Recurrence; Selective Serotonin Reuptake Inhibitors; Social Behavior Disorders | 1998 |
The side effect burden associated with drug treatment of panic disorder.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzodiazepines; Citalopram; Clonazepam; Humans; Panic Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1998 |
Pharmacotherapy of social anxiety disorder: what does the evidence tell us?
Topics: Clonazepam; Comorbidity; Drug Therapy, Combination; Humans; Paroxetine; Phobic Disorders; Psychotropic Drugs; Secondary Prevention; Sertraline; Treatment Outcome | 2006 |
Combined pharmacotherapy and psychological therapies for post traumatic stress disorder (PTSD).
Topics: Adolescent; Adult; Child; Child Abuse, Sexual; Clonazepam; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Humans; Male; Paroxetine; Randomized Controlled Trials as Topic; Refugees; Selective Serotonin Reuptake Inhibitors; Sertraline; Stress Disorders, Post-Traumatic | 2010 |
Pharmacological treatments in panic disorder in adults: a network meta-analysis.
Topics: Adult; Alprazolam; Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzodiazepines; Clomipramine; Clonazepam; Desipramine; Diazepam; Fluoxetine; Humans; Network Meta-Analysis; Panic Disorder; Paroxetine; Reboxetine; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Venlafaxine Hydrochloride | 2023 |
6 trial(s) available for paroxetine and clonazepam
| Article | Year |
|---|---|
Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Clonazepam; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Panic Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors; Time Factors | 2003 |
Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder.
Topics: Adult; Anti-Anxiety Agents; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Paroxetine; Personality Assessment; Phobic Disorders; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2004 |
Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine.
Topics: Adolescent; Adult; Agoraphobia; Clonazepam; Female; Humans; Male; Middle Aged; Panic Disorder; Paroxetine; Psychiatric Status Rating Scales; Treatment Outcome; Young Adult | 2011 |
Randomized, open naturalistic, acute treatment of panic disorder with clonazepam or paroxetine.
Topics: Adolescent; Adult; Clonazepam; Female; Humans; Male; Middle Aged; Panic Disorder; Paroxetine; Time Factors; Treatment Outcome; Young Adult | 2011 |
A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine.
Topics: Adolescent; Adult; Anticonvulsants; Brazil; Clonazepam; Drug Therapy, Combination; Female; Humans; Interview, Psychological; Long-Term Care; Male; Middle Aged; Panic Disorder; Paroxetine; Personality Inventory; Prospective Studies; Retreatment; Selective Serotonin Reuptake Inhibitors; Young Adult | 2012 |
A 6-Year Posttreatment Follow-up of Panic Disorder Patients: Treatment With Clonazepam Predicts Lower Recurrence Than Treatment With Paroxetine.
Topics: Adult; Clonazepam; Female; Follow-Up Studies; GABA Modulators; Humans; Male; Middle Aged; Panic Disorder; Paroxetine; Predictive Value of Tests; Prospective Studies; Recurrence; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome; Young Adult | 2017 |
14 other study(ies) available for paroxetine and clonazepam
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Paroxetine and akathisia.
Topics: Akathisia, Drug-Induced; Clonazepam; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Male; Middle Aged; Neurologic Examination; Paroxetine; Propranolol | 1995 |
Successful treatment of night terrors and somnambulism with paroxetine.
Topics: Clonazepam; Drug Therapy, Combination; Female; Humans; Middle Aged; Paroxetine; Polysomnography; Sleep Wake Disorders; Somnambulism | 1994 |
Serotonin turnover rate, [3H]paroxetine binding sites, and 5-HT1A receptors in the hippocampus of rats subchronically treated with clonazepam.
Topics: Animals; Binding Sites; Buspirone; Clonazepam; Dose-Response Relationship, Drug; Hippocampus; Male; Paroxetine; Radioligand Assay; Rats; Rats, Sprague-Dawley; Serotonin; Time Factors | 1995 |
Possible serotonin syndrome from paroxetine and clonazepam.
Topics: Adult; Clonazepam; Contraindications; Drug Interactions; Female; GABA Modulators; Humans; Nervous System Diseases; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Syndrome | 1998 |
Neonatal withdrawal syndrome following in utero exposure to paroxetine, clonazepam and olanzapine.
Topics: Antidepressive Agents, Second-Generation; Benzodiazepines; Clonazepam; Humans; Infant, Newborn; Male; Neonatal Abstinence Syndrome; Olanzapine; Paroxetine; Respiratory Insufficiency; Serotonin Syndrome | 2007 |
Cost-effectiveness analysis of burning mouth syndrome therapy.
Topics: Amisulpride; Antidepressive Agents; Burning Mouth Syndrome; Clonazepam; Cost-Benefit Analysis; Decision Trees; Dental Care; Drug Costs; Health Care Costs; Humans; Paroxetine; Sertraline; Sulpiride | 2012 |
Refractory social anxiety disorder.
Topics: Adult; Clonazepam; Drug Resistance; Drug Therapy, Combination; Female; Humans; Paroxetine; Phobia, Social; Pregabalin; Psychotropic Drugs | 2017 |
Koro in panic disorder: Beyond a culture bound phenomena.
Topics: Adult; Antidepressive Agents, Second-Generation; Clonazepam; Culture; GABA Modulators; Humans; India; Koro; Male; Panic Disorder; Paroxetine | 2018 |
COVID-19 Pandemic-Induced Panic Disorder.
Topics: Adult; Betacoronavirus; Clonazepam; Coronavirus Infections; COVID-19; Humans; Male; Pandemics; Panic Disorder; Paroxetine; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Effects of central nervous system drugs on androgen, estrogen α, glucocorticoid, and thyroid receptors.
Topics: Androgens; Animals; Carbamazepine; Central Nervous System Agents; CHO Cells; Clonazepam; Cricetinae; Cricetulus; Estrogen Receptor alpha; Estrogens; Fluoxetine; Glucocorticoids; Luciferases, Firefly; Paroxetine; Receptors, Androgen; Receptors, Glucocorticoid; Sertraline; Thyroid Gland | 2022 |